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Abstract
The availability of direct oral anticoagulants (DOACs) has caused a paradigm shift in thrombosis management.
DOAC profiles do not differ greatly, though they are quite different from that of warfarin, whereas their dosage
and dose regimens are not consistent. The direct thrombin inhibitor dabigatran seems to obstruct tenase by
inhibiting thrombin generated in the initial phase and feedback to the amplification phase of cell-based
coagulation reactions. Factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) mainly inhibit factor Xa activity of
the prothrombinase complex in the propagation phase. The dose regimens of these inhibitors can be classified
into once (rivaroxaban, edoxaban) and twice (dabigatran, apixaban) daily. On the other hand, their plasma
elimination half-life times are similar, which can be explained by differences in the type of aimed anticoagulation, such
as persistent (e.g., warfarin) and intermittent (e.g., low-molecular-weight heparin). Because of the differences among
DOACs, an indicator is necessary to compare them. We investigated relative potency to compare dosage and intensity
by calculation of conversion using a profile comprised of molecular weight, bioavailability, protein-binding rate, inhibitory
constant, and dosage. We found that the relative potencies were different, with that of apixaban higher than edoxaban
(60 mg) and nearly twice that of rivaroxaban. However, dabigatran could not be evaluated with this profile, likely due to
its different mode of action. These results suggest that rivaroxaban and apixaban differ in regard to anticoagulation type,
as the former shows persistent and the latter intermittent anticoagulation.
Keywords: Anticoagulant therapy, Direct oral anticoagulant (DOAC), Warfarin, Stroke prevention in atrial fibrillation (SPAF),
Relative potency
Introduction
It is not unusual for doctors in the intensive care unit
(ICU) to treat patients who are taking direct oral anticoagu-
lant (DOAC) medication. DOACs are mainly used for the
prevention of cardiac embolism caused by atrial fibrillation
(AF), in addition to treatment of deep vein thrombosis and
pulmonary embolism. AF patients tend to be elderly and
their number is increasing; thus, it is thought that the num-
bers of patients receiving DOACs will increase considerably
in the near future. Since DOAC administration may have
complicated effects on a healthy condition as well as exam-
ination results, additional information about these drugs
and their use for anticoagulant therapy is considered to be
necessary for physicians working in the ICU.
With the recent availability of DOAC agents (profiles
summarized in Table 1), thrombosis management has
entered a new era [1, 2], while warfarin has played the
leading role in this field for more than five decades.
Among available DOACs, dabigatran etexilate (hereafter
referred to as dabigatran) is the only oral anticoagulant
that functions as a thrombin inhibitor and pro-drug,
while the others (rivaroxaban, apixaban, edoxaban) func-
tion as activated factor X (FXa) inhibitors in an active
form. These drugs vary in regard to bioavailability, renal
excretion rate, and liver metabolism, while their plasma
elimination half-life is comparable at around 12 h. Fur-
thermore, their short acting profiles and modes of action
are quite different from those of warfarin.
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Dabigatran and rivaroxaban were approved for clinical
use as DOACs in European countries in 2008, after
which edoxaban was approved in Japan and apixaban in
Europe in 2011. These four agents are now available for
clinical use to prevent venous thromboembolism (VTE)
and mainly administered after major orthopedic surgery. In
addition, they have received approval for cases of stroke
prevention in atrial fibrillation (SPAF), while edoxaban, riv-
aroxaban, and apixaban have been approved for the treat-
ment of acute deep vein thrombosis (DVT) and pulmonary
thromboembolism (PTE). For SPAF cases, rivaroxaban and
edoxaban, which have a relatively shorter half-life among
DOACs, are administered once daily, while dabigatran and
apixaban, which have a relatively longer half-life, are given
in twice-daily regimens. When considering their half-life
values, these administration protocols do not appear to be
ideal. Although the efficacy and safety of all available
DOACs have been demonstrated in clinical studies, the
rationale for their dose regimens is unclear, though an indi-
cator useful for comparing them has not been previously
reported. In the present study, we attempted to develop
such an indicator using a profile comprised of molecular
weight, bioavailability, protein-binding rate, inhibitory con-
stant, and dosage and then investigated the relative potency
of each DOAC to compare dosage and intensity.
Inhibitory effects of DOACs in cell-based coagulation
reactions
For considering the anticoagulant mechanism of DOACs,
the cell-based coagulation reaction [3] method proposed by
Hoffman is relatively useful (Fig. 1). The presence of tissue
factor (TF) is revealed in endothelial cells or peripheral
monocytes by physicochemical coagulation stimulation,
such as endotoxin or immune complex of antiphospholipid
antibodies, resulting in the formation of a small amount of
thrombin, initial thrombin (initiation phase). Initial throm-
bin activates nearby platelets and coagulation factors except
for fibrinogen. Tenase (X-ase) is then formed with FXIa,
FIXa, and FVIIIa on the negative-charged phospholipid
membrane of activated platelets, and FXa is converted from
FX by X-ase. FXa forms a prothrombinase complex consist-
ing of FVa and FXa on activated platelets, and thrombin is
formed by that complex. This thrombin again activates
platelets and coagulation factors (amplification phase),
inducing the production of large amounts of FXa and
Table 1 Characteristics of direct oral anticoagulants
Dabigatran Rivaroxaban Edoxaban Apixaban
Inhibition target Factor IIa Factor Xa Factor Xa Factor Xa
Pro-drug Yes No No No
Liver metabolism ca. 20 % ca. 66 % NR NR
Renal excretion rate 80 % 36 % 35 % 25 %
Elimination half-life 14–17 h 7–11 h 9–11 h 10–14 h
Bioavailability 6.5 % 80–100 % 50 % 50 %
Interaction P-gp 3A4/2 J2, P-gp 3A4, P-gp 3A4, P-gp
Dosage form Capsule Tablet Tablet Tablet
IIa thrombin, Ca. approximately, NR not reported, P-gp p-glycoprotein
(inhibitor), 3A4/2J2 cytochrome P450 3A4/2J2 (inhibitor), 3A4 cytochrome
P450 3A4 (inhibitor)
Fig. 1 Cell-based coagulation reaction. Tissue factor is revealed in endothelial cells or peripheral monocytes by physicochemical coagulation
stimulation, resulting in the formation of a small amount of thrombin, initial thrombin (initial phase). Initial thrombin activates nearby platelets and
coagulation factors. Tenase (X-ase) is then formed on the negative-charged phospholipid membrane of activated platelets, and FXa is converted from
FX. FXa forms a prothrombinase complex on activated platelets, and thrombin is formed with that complex. This thrombin again activates platelets
and coagulation factors (amplification phase), inducing the production of large amounts of FXa and thrombin (propagation phase), resulting in
fibrin formation
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thrombin (propagation phase). The large amount of throm-
bin formed in the propagation phase plays a role to form
fibrin, resulting in thrombus formation.
Direct thrombin inhibitors such as dabigatran seem to
obstruct X-ase by inhibiting thrombin generated in the
initiation phase as well as feedback to the amplification
phase of cell-based coagulation reactions. X-ase consists
of activated intrinsic coagulation factors; thus, the influ-
ence of a direct thrombin inhibitor may be reflected in
activated partial thromboplastin time (APTT), which is
used as a screening test for intrinsic coagulation factors.
On the other hand, inhibitors of FXa are considered to in-
hibit the activity of factor Xa mainly in the prothrombi-
nase complex of the propagation phase. The effects of Xa
inhibitors may be reflected in prothrombin time (PT),
used as a screening test for extrinsic and common path-
way coagulation factors, as the prothrombinase complex
consists of activated common pathway coagulation factors.
DOACs are considered to show stronger anticoagulant
effects because these agents are able to inhibit X-ase and
prothrombinase complex, which are amplified systems in
the coagulation reaction. The purpose of the coagulation
reaction is to immediately generate excess thrombin with
X-ase and prothrombinase. Thus, it seems that anticoagu-
lants primarily act to inhibit these amplification systems.
Dosage and dose regimen of DOACs for each indication
The dosages and dose regimens of DOACs for VTE
prevention and SPAF indication are summarized in Table 2.
DOAC dosage and dose regimens have been investigated in
phase II as well as phase III studies with dose-adjusted
warfarin, which was selected according to phase II results.
Safety evaluations have also been performed in an SPAF
phase II study, though dose conclusions based on efficacy
evaluation are impossible due to the very low incidence of
stroke. Therefore, it seems that dosage and dose regimen
can be selected based on data from phase II studies for
other indications (primarily treatment of DVT and PTE),
or by utilizing data from a phase II study of SPAF and
then investigating using multiple arms in a phase III study.
According to published information, rivaroxaban and
apixaban were investigated by the former approach, while
dabigatran and edoxaban were investigated using the latter
in a three-arm design that compared low and high doses
of DOACs with dose-adjusted warfarin.
With dabigatran, a daily dose of 220 mg is used in a
twice daily regimen for SPAF, while a once daily regimen
has been selected for VTE prevention [4–6]. Indeed, for
three of the four available DOACs (edoxaban, rivaroxaban,
dabigatran), reduction of trough level using a once daily
regimen is recommended for at least VTE prevention.
Conversely, with apixaban, a twice daily regimen was re-
ported to be consistently selected for both VTE prevention
and SPAF indication, with the rationale apparently based
on a comparison conducted in a phase II VTE prevention
study [7]. Although the efficacy of 5 mg of apixaban given
once daily was nearly comparable to that of 2.5 mg given
twice daily, the bleeding incidence trends (major and all
bleeding) were not consistent in a comparison between
once and twice daily dosages with total daily doses ranging
from 5 to 20 mg. Thus, it is possible that the dosage and
dose regimen for each DOAC is not based on appropriate
or adequate evidence.
Differences in dose regimens among DOACs and their
antithrombotic effects
The anticoagulant activity of warfarin shows no significant
diurnal variation, and the agent provides a persistent anti-
coagulant effect by moderate reductions of several coagula-
tion factors. In terms of inhibition of thrombus formation,
persistent anticoagulation throughout the day may be an
advantage, though that is associated with an increased risk
of bleeding. On the other hand, DOACs show intermittent
anticoagulant effects because of their short half-lives. Inter-
mittent anticoagulation may raise a concern about sup-
pression of thrombus formation. A sufficient anticoagulant
effect was shown to be obtainable with a once daily regi-
men of low-molecular-weight heparin agents such as
enoxaparin, which have a shorter half-life of only 4 h
[8], and the clinical efficacy of intermittent anticoagula-
tion was proven when those were used as prophylaxis
for thrombosis.
Table 2 Doses of each DOAC for approved indications in Europe, the USA, and Japan
VTE prevention (V) SPAF (S) (S)/(V) daily
dose ratioDose Area Dose Area
Dabigatran 220 mg OD EU 150 mg BID110 mg BID EU, JP 1–1.4
150 mg BID US –
Rivaroxaban 10 mg OD EU, US 20 mg OD EU, US 2
15 mg OD JP –
Apixaban 2.5 mg BID EU 5 mg BID EU, US, JP 2
Edoxaban 30 mg OD JP 60 mg OD30 mg OD EU, US, JP 2
The dose for edoxaban for SPAF has not yet been confirmed, though results of 30- and 60-mg administrations have been reported in phase III studies
OD once daily, BID twice daily, EU Europe, US United States of America, JP: Japan
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When a DOAC with a half-life of about 12 h is admin-
istered twice daily at 12-h intervals, the next dose is
given at around the half-life time point. Theoretically,
the plasma concentration at the trough is maintained at
a level higher than half of the peak plasma concentration.
In practice, a certain level of the plasma concentration
area overlaps the next one, which causes a steady increase
in the trough level [8]. In other words, if a DOAC is
administered with a twice daily regimen, the trough level
is increased, and the difference between the peak and
trough levels is reduced, which can be interpreted as
persistent anticoagulation similar to that seen with war-
farin. However, in clinical cases, the anticoagulant effect of
apixaban is satisfactorily maintained, without actual accu-
mulation. It is considered that the Ki value of apixaban is
lower as compared to other Xa inhibitors, though the
detailed reason for this phenomenon is unknown. On the
other hand, if a DOAC is administered as a once daily
regimen, there is a larger difference between the peak and
trough levels. At the trough level, hemostatic activity is
nearly normal, as most of the effect of the administered
DOAC disappears. This can be interpreted as intermittent
anticoagulation similar to that reported for low-molecular-
weight heparin, which has quite a short half-life of 4 h and
is administered in a once or twice daily regimen. These
issues are summarized in Fig. 2.
With intermittent anticoagulation, the risk of thrombus
formation during the period of no anticoagulation around
the trough should be considered. In normal subjects,
physiological coagulation inhibitors, such as tissue factor
pathway inhibitor (TFPI) and the thrombomodulin (TM)-
protein C system, as well as antithrombin (AT) and
fibrinolytic activities likely act to prevent thrombus forma-
tion over the endocardium of the left atrial appendage.
However, in patients with atrial fibrillation, a sufficient
level of physiological anticoagulation does not seem to be
obtainable; thus, they tend to have a risk of thrombosis.
Interestingly, it was reported that decreased expressions of
both mRNA and proteins of TFPI and TM were found in
left atrial cells of rapid pacing model rats in comparison
with those from healthy rats [9]. On the other hand, other
physiological coagulation inhibitors such as AT exists in
these patients if TFPI and the TM-protein C system are
impeded, and some anticoagulant effects by AT are
expected for the prevention of thrombosis and fibrinolytic
activity, even in patients with atrial fibrillation. This weak
endogenous anticoagulation effect is considered to remain
even when the plasma concentration of the administered
DOAC is reduced. Therefore, it may enable the use of
DOACs in a once daily regimen in which the anticoagu-
lant effect disappears at the trough phase, though the risk
of thrombosis increases as compared with that at the peak
phase.
With edoxaban, a higher bleeding rate was reported in
cases with a twice daily regimen as compared to once at
the same daily dose [10]; thus, once daily is recommended
for that drug. A once daily regimen is also recommended
for rivaroxaban for similar reasons [11, 12]. On the other
hand, apixaban showed comparable efficacy and safety
with once and twice daily regimens for VTE prevention
after total knee arthroplasty [7], as shown in Table 2. With
a direct thrombin inhibitor, a once daily regimen is not
selected due to inadequate efficacy. While both regimens
are available for Xa inhibitors, once daily is recommended
for rivaroxaban and edoxaban based on better safety pro-
files and twice daily for apixaban because of better
efficacy.
Relative potency of DOAC
As noted above, DOAC dosages were determined based
on the results of phase I and/or II trials and divided into
normal and reduced doses. In addition, the effects were
compared with those of warfarin therapy in worldwide
large-scale clinical tests. Nevertheless, it is difficult to
Persistent type Intermittent type
Unfractionated heparin
Half-life: ca. 1 hour
Continuous infusion
Vitamin K antagonists: warfarin, etc.
Half-life: 55-133 hours
Oral administration, once daily
Low molecular weight heparin
Half-life: ca. 3-4 hours
Subcutaneous injection, once or twice daily
Direct thrombin inhibitor: argatroban
Half-life: ca. 0.5 hours
Three-hour infusion, twice daily
Indirect Xa Inhibitor: fondaparinux
Half-life: 14-17 hours
Subcutaneous injection, once daily
Direct thrombin inhibitor: dabigatran
Half-life: 14-17 hours
Oral administration, twice daily
Direct Xa inhibitor: apixaban
Half-life: 10-14 hours
Oral administration, twice daily
Direct Xa inhibitor: rivaroxaban
Half-life: 7-11 hours
oral administration, once daily
Direct Xa inhibitor: edoxaban
Half-life: 9-11 hours
Oral administration, once daily
Fig. 2 Anticoagulation based on duration of action with consideration of half-life and dose regimen
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directly compare the effects among DOACs, though a
comparison of each drug with the effect of warfarin
therapy is possible. Furthermore, the warfarin therapy
groups in those past clinical trials of DOACs were not
comprised of the same members and their backgrounds
differed, making it difficult to compare the effects of
each DOAC. Nevertheless, some indicators are useful to
examine DOAC regimens at different dosages; thus, we
attempted to compare their potency using drug-related
parameters. With an oral medication, the amount of
drug that appears in plasma can be approximately calcu-
lated using dose, bioavailability, and protein-binding
ratio. Furthermore, by adding the inhibition constant to
this scheme, the extent of inhibition of the target coagu-
lation factor in blood can be calculated for each DOAC.
Using this method, we first calculated the potency of
20 mg of rivaroxaban and then compared potencies
based on that of rivaroxaban, with the results shown in
Table 3. The profile of each DOAC (molecular weight,
bioavailability, protein-binding rate, inhibitory constant)
was essentially gathered from the detailed review of
Eriksson BI et al. [13]. However, some parameters were
not used in that study; thus, the bioavailability of rivar-
oxaban and molecular weight and bioavailability of edox-
aban were obtained from the review of Harbrecht U [1],
and the protein-binding rate of edoxaban was obtained
from the original report of Ogata K et al. [14]. We ini-
tially attempted to convert the potency of an Xa inhibi-
tor in comparison with dabigatran as the standard,
though those could not be compared, likely because of
their different pharmacological actions, since the volume
of thrombin is much larger than that of Xa. Thus, the Ki
value of a thrombin inhibitor cannot be compared with
that of an Xa inhibitor, since Ki is calculated from the
concentrations of free enzymes and free inhibitor, and
their complex. As a result, conversion was done using
rivaroxaban, the first clinically available Xa inhibitor, as
the standard.
We found it interesting that our potency calculation
findings showed that the doses of apixaban and edoxa-
ban were comparable even though the dose regimens
were different, and much higher than rivaroxaban at its
customary dose. With reduced doses, edoxaban was
found to be nearly comparable to rivaroxaban; hence,
apixaban remained even higher. However, the standard
daily dose of DOACs, excluding dabigatran, for SPAF is
twice that used for VTE prevention (20 and 10 mg,
respectively, for rivaroxaban; 10 and 5 mg, respectively,
for apixaban); thus, the daily dosage of edoxaban is most
likely to be 60 mg (30 mg when given twice daily). If that
is true, it is very interesting that the potency of edoxaban
at 60 mg was shown to be similar to that of apixaban at
10 mg despite the different dose regimens and doses
selected from various clinical studies.
Although the dose of apixaban is 5 mg, lowest among
available DOACs, its anticoagulant efficacy seems to be
greater than that of rivaroxaban and edoxaban when based
on this comparison. Moreover, our findings suggest that
apixaban therapy can maintain a persistent level of anticoa-
gulation similar to that shown by warfarin by administering
as a twice daily regimen, which provides more than 90 % of
the potency of rivaroxaban (equivalent to 18.68 mg of rivar-
oxaban twice daily), while it also maintains an intensity
close to the peak obtained with a once daily regimen of
Table 3 Potency conversion of DOAC
Rivaroxaban Dabigatran Apixaban Edoxaban
Molecular weight (Da) 436 628 460 548
(a) Molecular weight ratio to rivaroxaban 1 1.44 1.06 1.26
Bioavailability (%) 90*a 6.5 66 47.5*c
(b) Bioavailability ratio to rivaroxaban 1 13.85 1.36 1.89
Protein binding (%) 93.5*b 35 87 49.5*d
(c) Protein-binding ratio to rivaroxaban 1 0.37 0.93 0.53
Inhibitory constant; Ki (nM) 0.4 4.5 0.08 0.56
(d) Ki ratio to rivaroxaban 1 11.25 0.20 1.40
(A) Total ratio to rivaroxaban = (a)X(b)X(c)X(d) 1 83.99 0.27 1.77
(B) SPAF customary daily dose (mg) 20 300 10 60
Potency conversion; matching dose for customary
dose of rivaroxaban (B)/(A)
20 3.57 37.35 33.99
(C) SPAF reduced daily dose (mg) 15 220 5 30
Potency conversion; matching dose for reduced
dose of rivaroxaban (C)/(A)
15 2.62 18.68 17.00
*Average from a80–100, b92–95, c45–50, d40–59
SPAF stroke prevention in atrial fibrillation, Ki inhibitory constant
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rivaroxaban. This would suggest that the level of anticoagu-
lation provided by apixaban is quite different from that by
rivaroxaban. In fact, even a reduced dose of apixaban
(2.5 mg twice daily) nearly matches the customary dose of
20 mg of rivaroxaban given daily (18.68 mg). With edoxa-
ban, when 60 mg is given, the potency is higher than that
of rivaroxaban and lower than that of apixaban, while the
potency of a 30-mg dose is intermediate between the
normal and reduced dose of rivaroxaban. A comparison of
the potency of reduced doses of three different Xa inhibi-
tors showed a lower level of difference as compared with
normal doses. However, the dose reduction criteria in each
study were different, and the percentage of subjects in the
dose-reduced group receiving apixaban was different as
compared to those in the rivaroxaban and edoxaban groups
(4.7, 21.0, and 25.3 %, respectively) [15–17], Therefore, the
interpretation of findings for comparison of potency of a
reduced dose is not possible at this time.
As described above, the present comparison of potencies
may contribute to a better understanding of the purpose of
anticoagulant therapy, which can be adjusted by selecting
either a once or twice daily regimen. However, since the
only data available were obtained under varying circum-
stances during drug development phases, clinical outcomes
cannot be directly compared at this time and should not be
considered accurate. In addition, it is not yet clear which
DOAC or regimen is better for a specific condition. With
additional accumulation of clinical findings, comparisons in
regard to persistent and intermittent anticoagulation will be
possible.
Conclusions
It is thought that the numbers of patients receiving
DOACs will increase considerably in the near future.
Therefore, additional information about these drugs and
their use for anticoagulant therapy is considered to be
necessary for physicians working in the ICU. As it was
difficult to directly compare the effects among DOACs,
we attempted to compare their potency using drug-related
parameters. With our results, the present comparison of
potencies may contribute to a better understanding of the
purpose of anticoagulant therapy.
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